Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children

Overview

The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity )

• The severity of bronchiectasis will be assessed using forced expiratory volume in 1s (FEV1), and bronchiectasis severity scores which included bronchiectasis severity index (BSI) , FEV1, chronic colonization, extension of lobes and dyspnea which were performed to assess non-CF bronchiectasis patients. BSI score * This score incorporates 9 variables. The total score is calculated by summing the scores for each variable and can range from 0 to 26 points. According to the overall score, patients are classified into three classes: patients with low BSI score (0---4 points), intermediate BSI score (5---8 points), high BSI score (≥9 points) * chest X ray and HRCT of the chest: to assess the radiological severity of bronchiectasis using the radiological findings will be measured by assessing the most recent chest X ray and HRCT of the chest performed in the last six months using Bhalla score(10) * Culture and sensitivity from bronchoalveolar lavage for isolation of pseudomonas aeruginosa and any other organism. * Sputum procalcitonin level was measured in BAL samples using bronchoscopy. * Bronchoscopy: would be undertaken when the children were in a stable clinical condition as part of their annual review

Conditions

Interventions

Eligibility

Outcomes

Central Contacts